Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

Platelets

Volumn 19, Issue 4, 2008, Pages 275-281

  Payne, Christopher D ^a   Li, Ying G ^a   Brandt, John T ^a   Jakubowski, Joseph A ^a   Small, David S ^a   Farid, Nagy A ^a   Salazar, Daniel E ^b   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Antiplatelet Agents; Clopidogrel; P2Y12 receptor; Prasugrel; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMORRHOIDAL HEMORRHAGE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SERUM SICKNESS; SKIN ALLERGY; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TURBIDIMETRY; URTICARIA;

ADENOSINE DIPHOSPHATE; ADULT; ASPIRIN; DRUG TOXICITY; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; THIOPHENES; TICLOPIDINE;

EID: 38949144302     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100801891640     Document Type: Article

References (25)

1. Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH, for the CLASSICS investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102(suppl 6):624-629.
2. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr, Jacobs AK, Kern MJ, King SB, III, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-e286.
3. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann F-J. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
4. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn H-P, Büttner HJ, Neumann F-J. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-2564.
5. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: Implications for thrombotic events and restenosis. Platelets 2004;15:95-99.
6. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516.
8. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
9. 12 receptor antagonist activity. Semin Thromb Hemost 2005;31:184-194.
10. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. a review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25:357-374.
11. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-66.e16.
12. Payne CD, Li YG, Small DS, Ernest CS III, Farid NA, Jakubowski JA, Brandt JT, Salazar D, Winters KJ. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-562.
13. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173.
14. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E for the JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373.
15. Wiviott SD, Antman EM, Gibson M, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E, for the TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627-635.
16. Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985;60:635-642.
17. Armitage, P, Berry, G. Statistical Methods in Medical Research, 3rd ed. Oxford: Blackwell Scientific Publications; 1994. pp. 154-174.
18. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
19. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schömig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004;110:1916-1919.
20. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Nessel CC, Schwabe KD, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008;121:527-534.
21. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545-1551.
22. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31:174-183.
23. Weerakkody GJ, Jakubowski JA, Brandt JT, Farid NA, Payne CD, Zhu J, Warner MR, Naganuma H, Winters KJ. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel vs. prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007;100:331-336.
24. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-716.
25. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Schömig A. A double-blind randomized comparison between two different clopidogrel maintenance doses after percutaneous coronary intervention (ISAR-CHOICE 2 Trial). Eur Heart J 2006;27(S1):863 (abstract 5039).